Loading stock data…
Tandem Diabetes Care, Inc. (TNDM)
$15.83-0.41 (-2.52%)
After Hours$16.23+0.40 (+2.53%)· Last close Jun 29
Tandem Diabetes Care, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Tandem Diabetes Care, Inc. in the Healthcare sector is trading at $15.83 with a market capitalization of $1.2B. Wall Street consensus targets $28.88 (20 analysts), implying a +82.4% move over the next 12 months. The stock is currently 47% below its 52-week high of $29.65, remaining 14.9% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: MACD remains below its signal line. The Whystock Score of 35/100 signals elevated caution as multiple indicators diverge.
Ecosystem Influences
Sell-side targets imply +82.4% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Oversold momentum (RSI 34) — potential for technical mean-reversion
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $247.22M↓ | $290.38M↑ | $249.25M↑ | $240.68M↑ | $234.42M |
| Gross Profit | $136.79M↓ | $167.46M↑ | $134.29M↑ | $125.86M↑ | $118.41M |
| Operating Income | -$17.43M↓ | $8.29M↑ | -$22.86M↑ | -$31.86M↑ | -$120.88M |
| Net Income | -$20.39M↓ | -$589,000↑ | -$21.16M↑ | -$52.40M↑ | -$130.56M |
Peer Comparison
JNJUNHPFE
Fundamentals
Tandem Diabetes Care, Inc. designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. It's flagship products are the t:slim X2 insulin delivery system; and Tandem Mobi insulin ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.24B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.64
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-71.41%
Volume
Today's trading volume
1.38M
Recent News
1 Mooning Stock with Impressive Fundamentals and 2 We Find Risky
The stocks featured in this article are seeing some big returns. Over the past month, they’ve outpaced the market due to some combination of positive news, upbeat results, or supportive macro developments. As such, investors are taking notice and bidding up shares.
Tandem Diabetes (TNDM): Buy, Sell, or Hold Post Q1 Earnings?
Tandem Diabetes has gotten torched over the last six months - since December 2025, its stock price has dropped 25.8% to $16.77 per share. This may have investors wondering how to approach the situation.
NeuroPace (NPCE) Down 0.6% Since Last Earnings Report: Can It Rebound?
NeuroPace (NPCE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
How The Investment Story For Tandem Diabetes Care (TNDM) Is Evolving Without New Analyst Targets
Tandem Diabetes Care enters this update with no changes to its existing price target, providing a clear baseline for how the stock is currently framed by the latest analyst narrative. With no new pricing signals to interpret, the focus shifts to what this stable target indicates about expectations already reflected in the story. As you read on, you will see how to track future revisions and stay informed about how the narrative around Tandem Diabetes Care develops from here. Analyst Price...
Wall Street Analysts See a 56.2% Upside in Tandem Diabetes Care (TNDM): Can the Stock Really Move This High?
The average of price targets set by Wall Street analysts indicates a potential upside of 56.2% in Tandem Diabetes Care (TNDM). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.